STAT April 7, 2024
A new analysis published Sunday challenges the clinical trial endpoint the cancer screening firm Grail is using to evaluate its blood test aimed at simultaneously detecting multiple types of tumors early.
Grail’s test, called Galleri, is available in the U.S. but not yet approved by the Food and Drug Administration or reimbursed by Medicare except as part of a particular clinical trial. According to reports...